American Trypanosomiasis (Chagas Disease)

Infectious Disease Clinics of North America

Volumn 26, Issue 2, 2012, Pages 275-291

  Rassi, Anis ^a   Marcondes de Rezende, Joffre ^b  

^a Anis Rassi Hospital   (Brazil)

^b Instituto de Gastroenterologia Sao Paulo   (Brazil)

Author keywords

American trypanosomiasis; Chagas disease; Chagas heart disease; Epidemiology; Treatment; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; NIFURTIMOX;

ABDOMINAL DISCOMFORT; AGRANULOCYTOSIS; ANOREXIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CHAGAS DISEASE; CLINICAL FEATURE; DIARRHEA; DISEASE COURSE; DISORIENTATION; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; GRANULOCYTOPENIA; HEADACHE; HEART DEATH; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIFE CYCLE; MEGACOLON; MEGAESOPHAGUS; MOOD CHANGE; MYALGIA; NAUSEA; NEUROTOXICITY; NONHUMAN; ONYCHOLYSIS; PARASITE IDENTIFICATION; PARASITE TRANSMISSION; PARESTHESIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; POLYNEUROPATHY; REVIEW; SIDE EFFECT; SKIN ALLERGY; TASTE DISORDER; THROMBOCYTOPENIC PURPURA; TONSILLITIS; TREATMENT DURATION; TREATMENT OUTCOME; TRYPANOSOMA CRUZI; VERTIGO; VOMITING; WEIGHT REDUCTION;

CHAGAS DISEASE; CHRONIC DISEASE; HUMANS; NIFURTIMOX; NITROIMIDAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84861470158     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.03.002     Document Type: Review

References (45)

1. Chagas C. Nova tripanozomiase humana. Estudos sobre a morfolojía e o ciclo evolutivo de Schizotrypanum cruzi n. gen., n. sp., ajente etiolójico de nova entidade morbida do homen. Mem Inst Oswaldo Cruz 1909, 1:159-218. [in Portuguese].
2. Aufderheide A.C., Salo W., Madden M., et al. A 9,000-year record of Chagas disease. Proc Natl Acad Sci U S A 2004, 101:2034-2039.
3. Gorla D., Noireau F. Geographic distribution of Triatominae vectors in America. American trypanosomiasis (Chagas disease). One hundred years of research 2010, 209-231. Elsevier Inc, Burlington (VA). 1st edition. J. Telleria, M. Tibayrenc (Eds.).
4. Rassi A., Rassi A., Marin-Neto J.A. Chagas disease. Lancet 2010, 375:1388-1402.
5. Salvatella R. Organizacion panamericana de la salud. Estimacion cuantitativa de la enfermedad de chagas en las Americas 2006, Report no. OPS/ HDM/CD/425-6, Organizacion Panamericana de la Salud, Montevideo (Uruguay), [in Spanish].
6. WHO Chagas disease (American trypanosomiasis) fact sheet (revised in June 2010). Wkly Epidemiol Rec 2010, 85:334-336.
7. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 2003, 98:577-591.
8. Kirchhoff L.V. Epidemiology of American trypanosomiasis (Chagas disease). Adv Parasitol 2011, 75:1-18.
9. Kribs-Zaleta C. Estimating contact process saturation in sylvatic transmission of Trypanosoma cruzi in the United States. PLoS Negl Trop Dis 2010, 4:e656.
10. Kirchhoff L.V., Rassi A. Chagas' disease and trypanosomiasis. Harrison's principles of internal medicine 2011, 1716-1721. McGraw-Hill, New York. 18th edition. D.L. Longo, A.S. Fauci, D.L. Kasper (Eds.).
11. Bern C., Montgomery S.P. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009, 49:e52-e54.
12. Gascon J., Bern C., Pinazo M.J. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010, 115:22-27.
13. Hidron A., Vogenthaler N., Santos-Preciado J.I., et al. Cardiac involvement with parasitic infections. Clin Microbiol Rev 2010, 23:324-349.
14. Rassi A., Rassi A., Little W.C. Chagas' heart disease. Clin Cardiol 2000, 23:883-889.
15. Marin-Neto J.A., Cunha-Neto E., Maciel B.C., et al. Pathogenesis of chronic Chagas heart disease. Circulation 2007, 115:1109-1123.
16. Rassi A., Rassi A., Rassi G.G. Fase aguda da doença de Chagas. Trypanosoma cruzi e doença de Chagas 2000, 231-245. Guanabara Koogan, Rio de Janeiro (Brazil), [in Portuguese]. 2nd edition. Z. Brener, Z.A. Andrade, M. Barral-Netto (Eds.).
17. Pinto A.Y., Valente S.A., Valente V da C., et al. Rev Soc Bras Med Trop 2008, 41:602-614. [in Portuguese].
18. Rassi A., Gabriel Rassi A., Gabriel Rassi S., et al. Arq Bras Cardiol 1995, 65:377-387. [in Portuguese].
19. Freitas H.F., Chizzola P.R., Paes A.T., et al. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas heart disease. Int J Cardiol 2005, 102:239-247.
20. Rassi A., Rassi S.G., Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol 2001, 76:75-96.
21. Rassi A., Rezende J.M., Luquetti A.O., et al. Clinical phases and forms of Chagas disease. American trypanosomiasis (Chagas disease). One hundred years of research 2010, 709-741. Elsevier Inc, Burlington (MA). 1st edition. J. Telleria, M. Tibayrenc (Eds.).
22. Bern C., Montgomery S.P., Herwaldt B.L., et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007, 298:2171-2181.
23. Rassi A., Rassi A., Little W.C., et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 2006, 355:799-808.
24. Rassi A., Rassi A., Rassi S.G. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 2007, 115:1101-1108.
25. Rassi A., Rassi A., Marin-Neto J.A. Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz 2009, 104(Suppl 1):152-158.
26. Rassi A., Dias J.C., Marin-Neto J.A., et al. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart 2009, 95:524-534.
27. Ministério da Saúde Brasil Rev Soc Bras Med Trop 2005, 38(Suppl 3):7-29. [in Portuguese].
28. Rassi A., Luquetti A.O. Specific treatment for Trypanosoma cruzi infection (Chagas disease). American trypanosomiasis 2003, 117-125. Kluwer Academic, Boston. K.M. Tyler, M.A. Miles (Eds.).
29. Control de La Enfermedad de Chagas. Série de Informes Técnicos de la OMS 1991, 811, Comité de Expertos de la OMS, Ginebra (Suiza), [in Spanish].
30. de Andrade A.L., Zicker F., de Oliveira R.M., et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996, 348:1407-1413.
31. Sosa Estani S., Segura E.L., Ruiz A.M., et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998, 59:526-529.
32. Control of Chagas disease: report of a WHO expert committee. World Health Organ Tech Rep Ser 2002, 905:1-109.
33. Mady C., Ianni B.M., de Souza J.L. Benznidazole and Chagas disease: can an old drug be the answer to an old problem?. Expert Opin Investig Drugs 2008, 17:1427-1433.
34. Issa V.S., Bocchi E.A. Antitrypanosomal agents: treatment or threat?. Lancet 2010, 376:768.
35. Rassi A., Rassi A., Marin-Neto J.A. Antitrypanosomal agents: treatment or threat?. Lancet 2010, 376:768-769. [authors' reply].
36. Viotti R., Vigliano C., Lococo B., et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006, 144:724-734.
37. Gallerano R.H., Sosa R.R. Resultados de um estúdio a largo plazo com drogas antiparasitárias em infectados chagásicos crônicos. Rev Fed Arg Cardiol 2001, 30:289-296. [in Spanish].
38. Fabbro D.L., Streiger M.L., Arias E.D., et al. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007, 40:1-10.
39. Marin-Neto J.A., Rassi A., Morillo C.A., et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008, 156:37-43.
40. Villar J.C., Marin-Neto J.A., Ebrahim S., et al. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 2002, 1. CD003463.
41. Rassi A., Luquetti A.O., Rassi A., et al. Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am J Trop Med Hyg 2007, 76:58-61.
42. Apt W., Arribada A., Zulantay I., et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasitol 2005, 99:733-741.
43. Leslie M. Infectious diseases. Drug developers finally take aim at a neglected disease. Science 2011, 333:933-935.
44. Bocchi E.A., Fiorelli A. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. Ann Thorac Surg 2001, 71:1833-1838.
45. Feitosa G., dos Santos R.R., Rassi S., et al. Cell therapy in dilated chagasic cardiomyopathy: the MiHeart study. Eur Heart J 2010, 31(Suppl):323-324. [abstract].